Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 vaccine programmes are expected to cost poorer countries an additional 56.6% on health budgets, compared with just 0.8% on wealthy countries’ health expenditure, according to new data from the United Nations Development Programme (UNDP), the World Health Organisation (WHO) and the University of Oxford.

Vaccine being administrered

According to the research, inequity will have a 'lasting and profound impact' on socio-economic recovery in low and lower-middle income countries unless there is urgent action to make vaccines affordable and accessible to everyone.

With the current cost of vaccines calculated at an average US$15.80, and without immediate global financial support, low-income countries are forecast to see health costs soar by more than half, to vaccinate fully a target of 70% of their populations. But high-income countries would have to increase spending by just 0.8 percent to achieve the same results. This would account for half of low-income countries' projected GDP growth in 2021, against 0.2% for high-income countries.

These insights come from the Global Dashboard on Vaccine Equity , a joint initiative from UNDP, WHO and Oxford’s Blavatnik School of Government, which combines the latest COVID-19 vaccination information with the most recent socio-economic data. It illustrates why vaccine equity is not only critical to saving lives but also to driving a fairer and faster recovery from the pandemic.

Read the full story on the University of Oxford website.

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.